Elpiscience and Astellas collaborate for novel bispecific macrophage engager
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Lacosamide is indicated to treat partial-onset seizures
Receives registration of Valganciclovir powder for oral solution in Germany
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Subscribe To Our Newsletter & Stay Updated